Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in this application:

Listing of Claims:

1. (withdrawn) A method for the inhibition of post-operative adhesion formation in a body between tissue surfaces in a body cavity having been subjected to a surgical procedure comprising administering Pemirolast, or an analog thereof, directly to said tissue surfaces in said body cavity in amounts and under conditions effective to inhibit formation of adhesions thereon.

2. (withdrawn) The method of claim 1 wherein said Pemirolast or analog thereof is administered in cooperation with a delivery vehicle suitable for use in the local, non-systemic administration of a therapeutic agent to the body.

3. (withdrawn) The method of claim 2 wherein said delivery vehicle is selected from the group consisting of microcapsules, microspheres, barriers, liposomes, lipid foams, solutions, compositions, osmotic pumps, fibers, filaments, gels, foams and films.

4. (withdrawn) The method of claim 3 wherein said barrier is absorbable.

5. (withdrawn) The method of claim 1 wherein said Pemirolast is administered in combination with a therapeutic agent, said therapeutic agent administered in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

6. (withdrawn) The method of claim 5 wherein said therapeutic agent is selected from the group consisting of an anti-platelet, an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.

7. (withdrawn) The method of claim 1 wherein said Pemirolast analog is selected from the group consisting of 3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2-α]pyrim- idin-4-one, 7-Methyl-3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2- α]pyrimidin- -4-one, 8-Methyl-3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2- α]pyrimidin-4-one, 7-Ethyl-3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2- α]pyrimidin-4-one, 7-n-Butyl-3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2-α]pyrimidin-4-one, 7-Phenyl-3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2-α]pyrimidin-4-one, 7-Chloro-3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2- α]pyrimidin-4-one, 7,9-dimethyl-3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2- α]pyrimidin-4-one, 9-Ethyl-3-(1H-Tetrazol-5-yl)-4H-pyridol[1,2- α]pyrimidin-4-one, 8,9,1-,11-tetrahydro-3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1- α]isoquinol-4-one

8. (withdrawn) The method of claim 1 wherein said Pemirolast or analog thereof is administered in a single dose.

9. (withdrawn) The method of claim 1 wherein said Pemirolast or analog thereof is administered by sustained release.

10. (withdrawn) The method of claim 1 wherein said Pemirolast or analog thereof is administered by burst/sustained release.

11. (withdrawn) The method of claim 1 wherein said Pemirolast or analog thereof is administered at a level of from about 0.01 milligram per kilogram of the body to about 3,000 milligram per kilogram of the body.

12. (withdrawn) The method of claim 1 further comprising administering Pemirolast systemically to said body prior to said surgical procedure.

13. (withdrawn) The method of claim 1 wherein Pemirolast is administered systemically to said body prior to said surgical procedure in amounts and for a time effective to increase inhibition for formation of adhesions in said body when compared to

administration of Pemirolast directly to said tissue surfaces in said body cavity in said body without said systemic administration.

14. (currently amended) A delivery vehicle suitable for local, non-systemic administration of a drug to a body and directly to tissue within a body cavity having been subjected to a surgical procedure, said vehicle comprising Pemirolast or an analog thereof in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said Pemirolast to said tissue, wherein the delivery vehicle is selected from the group consisting of microcapsules, microspheres, barriers, liposomes, lipid foams, compositions, osmotic pumps, fibers, filaments, gels, foams and films, and wherein said delivery vehicle comprises a polymer selected from the group consisting of poloxamers, poly(orthoester)s, poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacryladmide)s, anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(l-lactide), poly(dl-lactide), poly(dl-lactide-co-glycolide)s, poly(l-lactide-co-glycolide)s, poly(e-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaamide)s and glyceride polymers.

15. (cancelled) The delivery vehicle of claim 14 selected from the group consisting of microcapsules, microspheres, barriers, liposomes, lipid foams, solutions, compositions, osmotic pumps, fibers, filaments, gels, foams and films .

16. (cancelled) The delivery vehicle of claim 15 comprising a polymer selected from the group consisting of poloxamers, poly(orthoester)s, poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacryladmide)s, anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(l-lactide), poly(dl-lactide), poly(dl-lactide-co-glycolide)s, poly(l-lactide-co-glycolide)s, poly(e-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaamide)s and glyceride polymers.

17. (currently amended) The delivery vehicle of claim ~~15~~ 14 wherein said liposome is

selected from the group consisting of L-alpha-distearoyl phosphatidylcholine, phosphatidylcholine, dipalmitoylphosphatidylcholine and egg phosphatidylcholine.

18. (currently amended) The delivery vehicle of claim ~~15~~ 14 wherein said solution comprises a crystalloid instillate selected from the group consisting of phosphate buffered saline, saline and lactated Ringer's solution.

19. (currently amended) The delivery vehicle of claim ~~15~~ 14 wherein said solution comprises viscous instillate comprising a carrier selected from the group consisting of dextrans, cyclodextrans, hydrogels, carboxymethylcellulose, poly(saccharide)s, hyaluronic acids, crosslinked hyaluronic acids and chondroitin sulfates.

20. (cancelled) The delivery vehicle of claim 15 wherein said barrier is absorbable.

21. (original) The delivery vehicle of claim 19 wherein said absorbable barrier is selected from the group consisting of hyaluronic acids, cellulosics derivatives, collagens, recombinant human collagen, polyethylene glycols, pluronics, chitin, chitosans, dextrans, glucoses, carbohydrates, gelatins, glycosaminoglycans, polyacrylamides, polyvinyl pyrrolidones, polyvinyl alcohols, polymethyacrylics, aliginates, starches and polypeptides.

22. (currently amended) The delivery vehicle of claim 14 ~~further~~ additionally comprising a second therapeutic agent in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

23. (original) The delivery vehicle of claim 22 wherein said therapeutic agent is selected from the group consisting of an anti-platelet, an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.

24. (original) The delivery vehicle of claim 14 wherein said vehicle provides for single dose administration of said Pemirolast or analog thereof.

25. (cancelled) The delivery vehicle of claim 14 wherein said vehicle provides for sustained release of said Pemirolast or analog thereof.

26. (cancelled) The method of claim 14 wherein said vehicle provides for burst/sustained release of said Pemirolast or analog thereof.

27. (original) The delivery vehicle of claim 14 comprising from about 0.01 milligram Pemirolast or analog thereof per kilogram of the body to about 3,000 milligram Pemirolast or analog thereof per kilogram of the body.

28. (currently amended) A composition suitable for local, non-systemic administration of a drug to a body and directly to tissue within a body cavity having been subjected to a surgical procedure, said composition comprising Pemirolast or an analog thereof in an amount effective to inhibit formation of post-operative adhesions upon local, non-systemic administration of said composition to said tissue, and a carrier suitable for local, non-systemic administration of said Pemirolast or analog thereof, wherein the carrier is selected from the group consisting of microcapsules, microspheres, barriers, liposomes, lipid foams, osmotic pumps, fibers, filaments, gels, foams and films, and wherein the carrier comprises a polymer selected from the group consisting of poloxamers, poly(orthoester)s, poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacryladmide)s, anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(l-lactide), poly(dl-lactide), poly(dl-lactide-co-glycolide)s, poly(l-lactide-co-glyco- lide)s, poly(e-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaamide)s and glyceride polymers.

29. (canceled) The composition of claim 28 wherein said carrier is selected from the group consisting of microcapsules, microspheres, barriers, liposomes, lipid foams, solutions, osmotic pumps, fibers, filaments, gels, foams and films.

30. (canceled) The composition of claim 29 wherein said carrier comprises a polymer selected from the group consisting of poloxamers, poly(orthoester)s, poly(vinyl alcohol)s, poly(anhydride)s, poly(methacrylate)s, poly(methacryladmide)s, anionic carbohydrate polymers, poly(hydroxybutyric acid)s, polyacetals, poly(l-lactide), poly(dl-lactide), poly(dl-lactide-co-glycolide)s, poly(l-lactide-co-glyco- lide)s, poly(e-caprolactone), polyglycolide, poly(p-dioxanone)s, poly(trimethylene carbonate), poly(alkylene diglycolate)s, poly(oxaester)s, poly(oxaamide)s and glyceride polymers.

31. (original) The composition of claim 28 wherein said composition provides for single dose administration of said Pemirolast or analog thereof.

32. (canceled) The composition of claim 28 wherein said composition provides for sustained release of said Pemirolast or analog thereof.

33. (canceled) The composition of claim 28 wherein said composition provides for burst/sustained release of said Pemirolast or analog thereof.

34. (currently amended) The composition of claim 28 comprising from about 0.01 milligram Pemirolast or analog thereof per kilogram of the body to about 3,000 milligram ~~Tranilast~~ Permirolast or analog thereof per kilogram of the body.

35. (currently amended) The composition of claim ~~29~~ 28 wherein said liposome is selected from the group consisting of L-alpha-distearoyl phosphatidylcholine, phosphatidylcholine, dipalmitoylphosphatidylcholine and and egg phosphatidylcholine.

36. (currently amended) The composition of claim ~~29~~ 28 wherein said solution comprises a crystalloid instillate selected from the group consisting of phosphate buffered saline, saline and lactated Ringer's solution.

37. (currently amended) The delivery vehicle of claim ~~29~~ 28 wherein said solution comprises viscous instillate comprising a carrier selected from the group consisting of

dextrans, cyclodextrans, hydrogels, carboxymethylcellulose, poly(saccharide)s, hyaluronic acids, crosslinked hyaluronic acids and chondroitin sulfates.

38. (cancelled) The delivery vehicle of claim 29 wherein said barrier is absorbable.

39. (currently amended) The composition of claim ~~29~~ 28 wherein said barrier is selected from the group consisting of hyaluronic acids, cellulosics derivatives, collagens, recombinant human collagen; polyethylene glycols, pluronics, chitin, chitosans, dextrans, glucoses, carbohydrates, gelatins, glycosaminoglycans, polyacrylamides, polyvinyl pyrrolidones, polyvinyl alcohols, polymethyacrylics, aliginates, starches and polypeptides.

40. (currently amended) The composition of claim 28 ~~further~~ additionally comprising a second therapeutic agent in an amount effective to provide the therapeutic effect intended by administration of said therapeutic agent.

41. (currently amended) The ~~delivery vehicle~~ composition of claim ~~39~~ 40 wherein said therapeutic agent is selected from the group consisting of an anti-platelet, an anti-fibrotic, an anti-inflammatory, an anti-proliferative and an agent that inhibits collagen synthesis.